CA
AZN icon

Crumly & Associates’s AstraZeneca AZN Stock Holding History

Crumly & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
+5,313
New +$999K 0.19% 70
2026
Q1 		– Sell
-4,056
Closed -$746K – 201
2025
Q4 		$746K Sell
4,056
-206
-5% -$36.1K 0.16% 85
2025
Q3 		$654K Buy
4,262
+727
+21% +$110K 0.14% 90
2025
Q2 		$494K Buy
3,535
+123
+4% +$17.2K 0.12% 101
2025
Q1 		$501K Sell
3,412
-130
-4% -$18.8K 0.14% 99
2024
Q4 		$464K Buy
3,542
+220
+7% +$30.8K 0.13% 101
2024
Q3 		$518K Buy
3,322
+71
+2% +$11.5K 0.14% 99
2024
Q2 		$507K Buy
3,251
+32
+1% +$4.82K 0.15% 95
2024
Q1 		$436K Buy
3,219
+99
+3% +$13.1K 0.11% 111
2023
Q4 		$420K Buy
3,120
+49
+2% +$6.37K 0.12% 105
2023
Q3 		$416K Buy
3,071
+20
+0.7% +$2.73K 0.16% 78
2023
Q2 		$437K Buy
3,051
+574
+23% +$84.5K 0.17% 79
2023
Q1 		$344K Sell
2,477
-4
-0.2% -$538 0.15% 86
2022
Q4 		$336K Buy
+2,481
New +$311K 0.13% 74

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

Crumly & Associates's AZN Position: Q2 2026 in Review

Crumly & Associates opened a new position in AstraZeneca (AZN) in Q2 2026: 5,313 shares worth $1.01M. The stake represents 0.19% of the portfolio and ranks #70 among its holdings. This is a return to the name: Crumly & Associates previously reported a position in AZN as recently as Q4 2025.

Crumly & Associates first reported a position in AZN in Q4 2022 and has held it in 14 quarters since. 443 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Crumly & Associates held 5,313 shares of AstraZeneca worth $1.01M as of Q2 2026.
  • AstraZeneca was a new Crumly & Associates position in Q2 2026.
  • AstraZeneca made up 0.19% of Crumly & Associates's portfolio in Q2 2026, its #70 holding.
  • Crumly & Associates first reported a position in AstraZeneca in Q4 2022 and has held it in 14 quarters since.
  • 443 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Crumly & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.